secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0001493152-24-051091
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA Pharmaceuticals replaces auditor Cherry Bekaert with Salberg; material weaknesses cited
--------------------------------------------------------------------------------

- Cherry Bekaert resigned as auditor effective Dec 16, 2024; no disagreements but noted material weaknesses in internal controls for 2022 and 2023.
- Salberg & Company P.A. engaged as new independent auditor for fiscal year ending Dec 31, 2024, effective Dec 18.
- Cherry Bekaert's prior reports included a going concern explanatory paragraph.
- No disagreements or reportable events other than the material weaknesses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000149315224051091/0001493152-24-051091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000149315224051091/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-051091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer